Business
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices
BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies, today highlighted new survey findings released by the Voices for Non-Opioid Choices (Voices) coalition following the first year of the Non-Opioids Prevent Addiction (“NOPAIN”) Act. Made up of more than 250 organizations dedicated to preventing opioid addiction before it starts, Voices is the nation’s leading nonpartis
About this update from Pacira Biosciences, Inc.
[{"type":"image","alt":"Pacira BioSciences","displaySize":"","headline":null,"caption":"Pacira BioSciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/04e0c8f8e2099937e616269a7f79e669"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oeRpxMnSSfjelY6qFBDpsw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/04e0c8f8e2099937e616269a7f79e669","width":300,"height":300}},"lazy":false},{"type":"text","content":"BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies, today highlighted new survey findings released by the Voices for Non-Opioid Choices (Voices) coalition following the first year of the Non-Opioids Prevent Addiction (“NOPAIN”) Act.","length":361,"tagName":"p"},{"type":"text","content":"Made up of more than 250 organizations dedicated to preventing opioid addiction before it starts, Voices is the nation’s leading nonpartisan coalition dedicated to ensuring patient access to non-addictive pain management approaches","length":231,"tagName":"p"},{"type":"text","content":"Data were gathered from a national awareness, trial, and usage (ATU) survey of nearly 750 hospitals, health systems, and ambulatory surgery center (ASC) directors of pharmacy, medical directors, surgeons, and anesthesiologists. Results illustrate the early impacts of the NOPAIN Act, which went into effect on January 1, 2025, with key highlights including:","length":357,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Eighty-five percent of facility representatives surveyed were aware of the legislation, and more than half (52 percent) of facilities surveyed had taken steps to increase utilization of qualifying non-opioid options.","length":216,"tagName":"p"}]},{"val":[{"type":"text","content":"More than 80 percent of those surveyed reported that the legislation has decreased opioid prescribing immediately after surgery (83 percent) and at discharge (88 percent); and","length":175,"tagName":"p"}]},{"val":[{"type":"text","content":"The majority of respondents report changing perioperative and postoperative pain management protocols (52 and 51 percent, respectively) to increase the use of non-opioids...